Moderna has dosed the first patients in a Phase I study of mRNA-1283, the company’s next-generation Covid-19 vaccine candidate. mRNA-1283 is a potential refrigerator-stable vaccine that is designed to allow easy distribution and administration across settings, especially in developing countries. The safety and immunogenicity of mRNA-1283 will be assessed in this Phase I dose-ranging study.
Japanese biopharma giant Takeda has announced a mutual agreement with IDT Biologika, a contract development and manufacturing organisation, to use its capacity previously reserved for Takeda’s dengue vaccine, TAK-003, to produce the single-shot Covid-19 vaccine developed by Janssen Pharmaceutical Companies. The capacity will be returned to Takeda for critical production of its dengue vaccine after three months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Fulgent Genetics, a technology company, has been awarded a contract by the US Centres for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples on a continuous basis by leveraging the company’s next-generation sequencing (NSG) capabilities. As per the agreement, Fulgent will sequence the genomes of random Covid-19 samples. Fulgent will use its NGS platform and sequencing data to perform a large-scale genomic survey of the virus using random samples from across the US.
